![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Lilly Pursues EUA for COVID-19 Antibody for High-Risk Patients
Lilly Pursues EUA for COVID-19 Antibody for High-Risk Patients
![Eli Lilly logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Eli-Lilly-logo.gif?t=1616695830&width=430)
October 8, 2020
Eli Lilly is seeking an Emergency Use Authorization (EUA) for its monoclonal antibody LY-CoV555 for treatment of high-risk patients diagnosed with mild-to-moderate COVID-19.
LY-CoV555, or bamlanivimab, which is being developed with Vancouver-based AbCellera, is a neutralizing antibody that targets the coronavirus’ spike protein.
Lilly says that trial data showed LY-CoV555, both as a monotherapy and in combination with another neutralizing antibody, LY-CoV016, is an effective treatment for high-risk COVID-19 patients.
Upcoming Events
-
21Oct